GlassScriptPhysician profile
Sherrie M Harrell
NPI 1811230691
$7,449.27
in general payments reported to CMS, 2019-2025
26 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,162 · 2022: $1,289 · 2023: $1,711 · 2024: $1,609 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,845 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.68 |
| Education | $152.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,982.54 | 2021-2025 | |
| Janssen Biotech, INC. | $856.08 | 2021-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $713.47 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.67 | 2021-2025 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $443.79 | 2021-2025 | Sutab, Suflave |
| Janssen Scientific Affairs, LLC | $440.09 | 2021-2025 | Stelara, Tremfya |
| Merck Sharp & Dohme LLC | $243.84 | 2021-2024 | Dificid, Zinplava |
| Gilead Sciences, INC. | $224.94 | 2025 | Epclusa |
| Ipsen Biopharmaceuticals, INC | $214.05 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $212.39 | 2024-2025 | Zenpep |
| Genzyme Corporation | $211.80 | 2022-2025 | |
| Pfizer INC. | $195.93 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $193.96 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $188.68 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $187.21 | 2024-2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $138.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.75 | 2023-2025 | Entyvio |
| Ardelyx, INC. | $115.23 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $58.88 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $58.22 | 2023 | Rebyota |
| Celgene Corporation | $49.11 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $30.46 | 2025 | Rezdiffra |
| Medtronic, INC. | $20.06 | 2022 | |
| Endogastric Solutions, INC | $18.71 | 2022 | |
| Novo Nordisk INC | $16.67 | 2025 | Wegovy |
| Shield Therapeutics INC | $13.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrie Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.